Drug record
What four public record sets show for aripiprazole. Saved Nov 10, 2026.
| Shortage | Not on the FDA shortage list | Details |
|---|---|---|
| Pharmacy cost | $0.117 each for the lowest-cost generic | Details |
| Medicare Part D, 2024 | $1.24 billion | Details |
| FDA recall records | 29 | Details |
Whether the FDA lists this drug as in short supply.
The list changes daily, and it covers the national supply. A pharmacy near you can be out of a drug that is not listed, or have one that is. See today's status.
The national average price retail pharmacies pay to buy it (NADAC).
The lowest-cost generic on file is Aripiprazole 5 Mg Tablet: pharmacies pay about $0.117 each, or $3.50 for 30.
| Product as surveyed | Type | Pharmacy pays | For 30 | Price since |
|---|---|---|---|---|
| ARIPIPRAZOLE 1 MG/ML SOLUTION | Generic | $0.395 per mL | — | Oct 21, 2026 |
| ARIPIPRAZOLE 10 MG TABLET | Generic | $0.119 per each | $3.56 | Oct 21, 2026 |
| ARIPIPRAZOLE 15 MG TABLET | Generic | $0.134 per each | $4.01 | Oct 21, 2026 |
| ARIPIPRAZOLE 2 MG TABLET | Generic | $0.121 per each | $3.62 | Oct 21, 2026 |
| ARIPIPRAZOLE 20 MG TABLET | Generic | $0.182 per each | $5.45 | Oct 21, 2026 |
| ARIPIPRAZOLE 30 MG TABLET | Generic | $0.183 per each | $5.48 | Oct 21, 2026 |
| ARIPIPRAZOLE 5 MG TABLET | Generic | $0.117 per each | $3.50 | Oct 21, 2026 |
| ARIPIPRAZOLE ODT 10 MG TABLET | Generic | $2.42 per each | $72.63 | Oct 21, 2026 |
| ARIPIPRAZOLE ODT 15 MG TABLET | Generic | $1.81 per each | $54.37 | Oct 21, 2026 |
| ABILIFY 10 MG TABLET | Brand | $18.62 per each | $558.47 | Oct 21, 2026 |
| ABILIFY 15 MG TABLET | Brand | $18.65 per each | $559.56 | Oct 21, 2026 |
| ABILIFY 2 MG TABLET | Brand | $18.67 per each | $560.13 | Oct 21, 2026 |
| ABILIFY 20 MG TABLET | Brand | $26.25 per each | $787.57 | Oct 21, 2026 |
| ABILIFY 30 MG TABLET | Brand | $26.23 per each | $786.95 | Oct 21, 2026 |
| ABILIFY 5 MG TABLET | Brand | $18.68 per each | $560.39 | Oct 21, 2026 |
| ABILIFY ASIMTUFII 720 MG/2.4 ML | Brand | $1,786.43 per mL | — | Oct 21, 2026 |
| ABILIFY ASIMTUFII 960 MG/3.2 ML | Brand | $1,781.74 per mL | — | Oct 21, 2026 |
| ABILIFY MAINTENA ER 300 MG SYR | Brand | $2,138.03 per each | $64,140.85 | Oct 21, 2026 |
| ABILIFY MAINTENA ER 300 MG VL | Brand | $2,142.36 per each | $64,270.81 | Oct 21, 2026 |
| ABILIFY MAINTENA ER 400 MG SYR | Brand | $2,852.00 per each | $85,560.04 | Oct 21, 2026 |
| ABILIFY MAINTENA ER 400 MG VL | Brand | $2,858.08 per each | $85,742.51 | Oct 21, 2026 |
| ARISTADA ER 1,064 MG/3.9 ML SYR | Brand | $994.17 per mL | — | Oct 21, 2026 |
| ARISTADA ER 441 MG/1.6 ML SYRN | Brand | $1,006.96 per mL | — | Oct 21, 2026 |
| ARISTADA ER 662 MG/2.4 ML SYRN | Brand | $1,007.79 per mL | — | Oct 21, 2026 |
| ARISTADA ER 882 MG/3.2 ML SYRN | Brand | $1,003.68 per mL | — | Oct 21, 2026 |
| ARISTADA INITIO ER 675 MG/2.4 | Brand | $1,026.91 per mL | — | Jan 1, 2026 |
This is not your price. NADAC is the national average that retail pharmacies pay to buy the drug, from the Medicaid survey for the week of Nov 11, 2026. What you pay adds the pharmacy's markup and dispensing fee and depends on your insurance or any discount card. "For 30" is shown only for products priced per tablet or capsule. Brand prices here are before any rebates.
Medicare Part D spending by product, from the latest annual file (2024).
In 2024, Medicare Part D plans and their members paid $1.24 billion for the 8 products below. That is up 16% from $1.07 billion in 2020.
| Product | 2024 spending | People | Per prescription | Per person, year | 2020 spending |
|---|---|---|---|---|---|
| Abilify Maintena Aripiprazole | $644.2 million | 29,911 | $2,738.85 | $21,538.34 | $460.3 million |
| Aristada Aripiprazole Lauroxil | $269.1 million | 13,102 | $2,987.84 | $20,537.02 | $203.1 million |
| Aripiprazole Aripiprazole | $245.3 million | 647,122 | $63.80 | $379.05 | $374.6 million |
| Abilify Asimtufii Aripiprazole | $63.1 million | 3,361 | $5,433.10 | $18,785.49 | — |
| Aripiprazole ODT Aripiprazole | $8.2 million | 2,349 | $636.72 | $3,471.72 | $5.9 million |
| Abilify Aripiprazole | $7.1 million | 1,480 | $991.08 | $4,780.60 | $24.5 million |
| Aristada Initio Aripiprazole Lauroxil,Submicr. | $3.0 million | 1,174 | $2,389.57 | $2,591.08 | $2.5 million |
| Abilify Mycite Aripiprazole | $90,322 | 16 | $1,704.20 | $5,645.15 | $92,372 |
Spending is the gross amount paid at the pharmacy by Part D plans and patients, before manufacturer rebates, which can be large for brand drugs. The same person can use more than one product, so people are not added up across rows. A dash means the file suppresses a small number or has no figure for that year.
Recalls reported to the FDA that name this drug.
The FDA has 29 recall records that name aripiprazole in the product description (21 Class II · 8 Class III). 7 are still marked ongoing.
Aripiprazole Tablets USP, Rx only, 30 mg, 30 tablets, Marketed by: Ajanta Pharma USA Inc., Bridgewater, NJ 08807, Made in India, NDC 27241-056-03.
Reason: Product Mix-Up: A bottle containing Voriconazole Tablets 50 mg was labelled and distributed as Aripiprazole Tablets USP 30 mg.
Aripiprazole Tablets, USP, 10 mg, 30-count bottles, Rx only, Manufactured by: Alken Laboratories Ltd., INDIA; Distributed by: Ascend Laboratories, LLC, Parsippany, NJ 07054. NDC: 67877-432-03
Reason: Superpotent drug
Abilify (aripiprazole), 15 mg tablets, packaged in 30 count bottles, RX only, Otsuka America Pharmaceutical, Inc., NDC 59148-009-13
Reason: Cross Contamination with Other Products
Abilify (aripiprazole), 5 mg tablets, packaged in 30 count bottles, RX only, Otsuka America Pharmaceutical, Inc., NDC 59148-007-13
Reason: Cross Contamination with Other Products
Abilify (aripiprazole), 10 mg tablets, packaged in a) 30 count bottles (NDC 59148-008-13) and b) 7 count blister packs (NDC 59148-008-95), RX only, Otsuka America Pharmaceutical, Inc.
Reason: Cross Contamination with Other Products
Abilify (aripiprazole), 30 mg tablets, packaged in 30 count bottles, RX only, Otsuka America Pharmaceutical, Inc., NDC 59148-011-13
Reason: Cross Contamination with Other Products
Aripiprazole Tablets, USP, 5 mg, 30 Tablets per bottle, Distributed by: Amneal Pharmaceuticals LLC, Bridgewater, NJ 08807. NDC: 65162-897-03
Reason: CGMP Deviations: Products were exposed to temperatures outside of the products labeled storage conditions.
Aripiprazole Tablets, USP, 20 mg, Rx Only, Packaged in 500-count bottle Manufactured by: Alkem Laboratories Ltd., INDIA Distributed by: Ascend Laboratories, LLC Parsippany, NJ 07054, NDC#: 67877-434-05
Reason: Out of specification (OOS) for Spectroscopic Identification test by IR.
Aripiprazole 5mg tablets, 30-count bottles, Rx only, Repackaged by: RemedyRepack Inc., Indiana, PA 15701, NDC 70518-2921-03
Reason: cGMP Deviations
Aripiprazole Tablets, USP 10 mg Rx Only, Packaged as a) 30-count bottle, NDC 16729-280-10, UPC 3 16729 28010 5; b) 100-count bottle, NDC 16729-280-01, UPC 3 16729 28001 3; Manufactured for: Accord Healthcare, Inc., Durham, NC 27703. Manufactured by: Intas Pharmaceuticals Limited, Pharmez, Ahmedabad-382 213. India
Reason: CGMP Deviations: recalling drug products following an FDA inspection.
Aripiprazole Tablets, USP 15 mg Rx Only, Packaged as: a) 30-count bottle NDC 16729-281-10, UPC 3 16729 28110 2; b) 100-count bottle NDC 16729-281-01, UPC 3 16729 28101 0; Manufactured for: Accord Healthcare, Inc., Durham, NC 27703. Manufactured by: Intas Pharmaceuticals Limited, Pharmez, Ahmedabad-382 213. India
Reason: CGMP Deviations: recalling drug products following an FDA inspection.
Aripiprazole Tablets, USP 2 mg, Rx Only, Packaged as a) 30-count bottle, NDC 16729-278-10, UPC 3 16729 27810 2; b) 100-count bottle, NDC 16729-278-01, UPC 3 16729 27801 10 Manufactured for: Accord Healthcare, Inc., Durham, NC 27703. Manufactured by: Intas Pharmaceuticals Limited, Pharmez, Ahmedabad-382 213. India
Reason: CGMP Deviations: recalling drug products following an FDA inspection.
A recall covers specific lots from one company, not every bottle of the drug. Records include combination products and compounded versions that name this ingredient. Class I is the most serious: use could cause serious harm. Class II may cause temporary or reversible harm. Class III is unlikely to cause harm. To check a bottle, match the lot number on the label. See the live list. Do not stop a medicine because of a recall without asking your pharmacist.
These are saved records as of Nov 10, 2026; the sources update daily to yearly. For current figures open the live report for aripiprazole. This page is public-record information, not medical advice.